Skip to content
Clinical Trials – home
Verifiedinfo

Pomeranian Medical University

Poland Ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland

  • 31 trials recruiting
  • Plasma cell myeloma · Acute myeloid leukaemia · Acute lymphocytic leukaemia
  • Adults and children

About Specializations

Pomeranian Medical University in Szczecin, Poland specialises in clinical trials of conditions such as Plasma cell myeloma, Acute myeloid leukaemia, Acute lymphocytic leukaemia, Phenylketonuria, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology and Hematology

The Pomeranian Medical University site in Szczecin conducts extensive research in neoplasms, with a strong focus on acute leukemias, lymphomas, myeloma, and solid tumors. These trials are designed to improve treatment effectiveness, reduce relapse risk, and support better outcomes for both adults and children with blood cancers and other malignancies.

  • Studies in acute lymphoblastic leukemia, acute myeloid leukemia, and lymphoblastic lymphoma are testing more effective cancer treatment strategies.
  • Research also includes classical Hodgkin lymphoma, multiple myeloma, and central nervous system lymphomas to evaluate new therapeutic options.
  • Trials in ovarian cancer, hepatoblastoma, hepatocellular carcinoma, and colorectal cancer aim to improve disease control and survival.

Much of this work focuses on comparing new combinations, improving response rates, and tailoring care to disease subtype and patient risk.

Pediatric and Rare Disease Research

This research portfolio includes a wide range of congenital, hereditary, and neonatal diseases, with particular attention to children and adolescents. The trials explore better ways to manage rare and complex conditions while preserving long-term health and quality of life.

  • Phenylketonuria, Prader-Willi syndrome, and growth hormone deficiency are studied to support metabolic control and growth.
  • Trials in congenital adrenal hyperplasia and presymptomatic type 1 diabetes aim to improve early disease management and prevention.
  • Research in children with leukemia and malignant liver tumors focuses on safer, more effective treatment approaches.

These studies often combine treatment evaluation with efforts to better understand rare pediatric disorders and their long-term impact.

Autoimmune, Rheumatologic, and Neurologic Conditions

The site has a strong presence in immune system diseases, musculoskeletal diseases, and nervous system diseases. Clinical trials are exploring new therapies for chronic inflammatory and autoimmune disorders that can significantly affect daily functioning.

  • Systemic lupus erythematosus, idiopathic inflammatory myopathy, and chronic graft versus host disease are being studied to improve immune control.
  • Trials in myasthenia gravis, CIDP, and secondary progressive multiple sclerosis aim to slow progression and improve symptoms.
  • Giant cell arteritis and SAPHO syndrome are included in research seeking better symptom relief and disease remission.

Overall, this area emphasizes testing targeted therapies that may reduce inflammation while improving function and quality of life.

Metabolic, Endocrine, and Genetic Disorders

Clinical research at the department also covers hormonal diseases, nutritional and metabolic diseases, and genetic phenomena. These trials are aimed at improving disease control, preserving organ function, and supporting healthier development over time.

  • Type 1 diabetes and Graves’ disease are studied to improve endocrine control and immune-related outcomes.
  • Phenylketonuria trials focus on lowering harmful metabolite levels and protecting neurocognitive development.
  • Research in Prader-Willi syndrome and growth hormone deficiency evaluates treatments intended to support growth and daily functioning.

These studies reflect a broader effort to refine long-term care for inherited and metabolic conditions across childhood and adulthood.

Cardiovascular, Respiratory, and Perioperative Care

Another major research stream involves cardiovascular diseases, respiratory tract diseases, and anesthesia and analgesia. The trials are focused on improving safety, preventing complications, and strengthening treatment outcomes in both surgical and medical settings.

  • Heart failure and myocardial injury after noncardiac surgery are studied to improve cardiovascular protection.
  • Chronic obstructive pulmonary disease, interstitial lung disease secondary to systemic sclerosis, and chronic rhinosinusitis with nasal polyps are included in respiratory research.
  • Perioperative studies examine general anesthesia and reversal of anticoagulation to support safer procedures.

At Centrum Wsparcia Badań Klinicznych, these trials aim to reduce risk and improve care around surgery, breathing disorders, and heart disease.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Unii Lubelskiej 171-252 SzczecinPoland
Recruiting now
31 trials
Conditions studied
49
Partner status
Verified

More sites in SzczecinPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

62 clinical trials

Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Scleroderma Research Foundation

Crohn's disease

Recruiting
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Agencja Badań Medycznych
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Agencja Badań Medycznych
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Etanercept
  • Sponsor:Agencja Badań Medycznych
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:F. Hoffmann-La Roche AG
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Deciphera Pharmaceuticals Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Rakuten Medical Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).